Anti-hypertensive drugs in children and adolescents.

Journal Article (Journal Article;Review)

Worldwide the prevalence of essential hypertension in children and adolescents continues to increase. Traditionally providers have used "off-label" drugs to treat pediatric hypertension, meaning that rigorous clinical trials of these drugs have not been specifically performed in pediatric patient populations. Consequently providers have extrapolated dosing, safety and efficacy from trials in adults. This practice is sub-optimal as children demonstrate unique differences in drug metabolism and response. Use of unstudied or understudied drugs increases risk of adverse events and/or can lead to sub-optimal efficacy. Recognizing these concerns, regulatory agencies have created financial incentives for industry to conduct pediatric clinical trials. These incentives, coupled with the emerging pediatric hypertension epidemic, have spurred over 30 clinical trials of anti-hypertensive drugs over the past 15 years and have resulted in labeling of 10 new drugs by the United States Food and Drug Administration for treatment of hypertension in children and adolescents. Unfortunately the financial incentive structures focus on newer drugs and drug classes. Consequently there is now a relative dearth of trial data for older but sometimes commonly prescribed pediatric antihypertensive drugs. This article reviews recent pediatric antihypertensive drug trials with a focus on trial design and endpoints, drug dosing, safety, efficacy and specific drug indications. We also review the available data and experience for some of the more commonly prescribed, but less well studied "older" pediatric antihypertensive drugs.

Full Text

Duke Authors

Cited Authors

  • Chu, PY; Campbell, MJ; Miller, SG; Hill, KD

Published Date

  • May 26, 2014

Published In

Volume / Issue

  • 6 / 5

Start / End Page

  • 234 - 244

PubMed ID

  • 24944754

Pubmed Central ID

  • PMC4062129

International Standard Serial Number (ISSN)

  • 1949-8462

Digital Object Identifier (DOI)

  • 10.4330/wjc.v6.i5.234


  • eng

Conference Location

  • United States